| 中文名称: | Etoposide phosphate disodium | ||||
|---|---|---|---|---|---|
| 英文名称: | Etoposide phosphate disodium | ||||
| 别名: | BMY-40481 disodium | ||||
| CAS No: | 122405-33-8 | 分子式: | C29H31Na2O16P | 分子量: | 712.5 |
| CAS No: | 122405-33-8 | ||||
| 分子式: | C29H31Na2O16P | ||||
| 分子量: | 712.5 | ||||
基本信息
|
产品编号： |
E10357 |
||||
|
产品名称： |
Etoposide phosphate disodium |
||||
|
CAS: |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
|
||||
|
分子式： |
溶于液体 |
|
|
||
|
分子量 |
712.50 |
|
|
||
|
化学名： |
BMY-40481 disodium |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
|
|||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
生物活性
|
产品描述 |
一种有效的抗癌 (anti-cancer) 化疗试剂和一种选择性拓扑异构酶 II (topoisomerase II) 抑制剂，可以防止 DNA 链的重新连接。 |
||
|
靶点 |
Topoisomerase II |
||
|
|
|||
|
体外研究 |
Etoposide phosphate disodium is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4' of the E ring of the etoposide molecule . Etoposide phosphate disodium (0-1μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50 values of 0.945μM; 0.375μM; and 1.437μM, respectively . Etoposide phosphate disodium (25μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells Cell Viability Assay |
||
|
|
Cell Line: |
FBXW+/+, FBXW-/- and p53-/- cell |
|
|
Concentration: |
0.025μM,0.05μM,0.075μM,0.1μM,0.2μM,0.4μM,0.6μM,0.8μM,1μM |
||
|
Incubation Time: |
72 hours |
||
|
Result: |
Inhibited HCT116 FBXW+/+, FBXW-/- and p53-/- cell growth as a concentration manner. |
||
|
|
Western Blot Analysis |
|
|
|
|
Cell Line: |
HCT116 FBXW7+/+ or FBXW7-/- cells |
|
|
Concentration: |
25μM |
||
|
Incubation Time: |
6 hours |
||
|
Result: |
Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7. |
||
|
体内研究 |
Etoposide phosphate (intravenous injection; 50, 100, or 150mg/kg; single dose) has clinical symptomology of progressiveataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice |
||
|
|
Animal Model: |
Female CD-1 mice |
|
|
Dosage: |
50, 100, or 150mg/kg |
||
|
Administration: |
Intravenous injection; single dose |
||
|
Result: |
Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM). |
||
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
